drugset / Trial / NCT03772288
A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) for TAK-659 when administered in combination with NKTR-214.
Timeline
- Start
- 2019-04-03
- Primary completion
- 2021-11-10
- Completion
- 2021-11-17
Outcome
Outcome not reported
Stopped (Business): “Business Decision: No Safety or Efficacy Concerns”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bempegaldesleukin | Protein / enzyme biologic | 0.003 mg/kg | Intravenous |
| Subject | Bempegaldesleukin | Protein / enzyme biologic | 0.006 mg/kg | Intravenous |
| Subject | mivavotinib | Small molecule | 40 mg | Oral |
| Subject | mivavotinib | Small molecule | 60 mg | Oral |
| Subject | mivavotinib | Small molecule | 80 mg | Oral |